Ignite Creation Date:
2025-12-24 @ 7:39 PM
Ignite Modification Date:
2025-12-25 @ 5:19 PM
Study NCT ID:
NCT07241403
Status:
COMPLETED
Last Update Posted:
2025-11-21
First Post:
2025-07-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
Sponsor:
Second Affiliated Hospital of Nanchang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-01-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-04-21
Completion Date Type:
ACTUAL
First Submit Date:
2025-07-25
First Submit QC Date:
None
Study First Post Date:
2025-11-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-16
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED